Abstract
Protein-protein interactions (PPIs) regulate crucial physiological and pathological processes. PPIs are considered a class of biological targets almost infeasible for small molecules because the binding surfaces are usually large and shallow. Peptides are molecules able to bind to these drug targets; they can be used as modulators and mimic one of the interaction partners. This review details the advances in in silico peptide design and experimental approaches for the evaluation of PPI-based peptides.